Wed Dec 15, 2021 – 12:47 pm EST
(LifeSiteNews) — President Joe Biden’s nominee to lead the FDA signaled his support for loosened restrictions on the abortion pill mifepristone and hopes for universal medical data collection at his Senate nomination hearing Tuesday.
Early in the hearing, nominee Dr. Robert Califf was asked by Sen. Richard Burr (R-NC) about his future advocacy for mifepristone and whether the drug should be removed from the FDA’s Risk Evaluation and Mitigation Strategy (REMS) protocol. According to the FDA, the REMS program addresses “certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.”
Califf responded that any future decision by the FDA would be data-driven: “As you are well aware a fundamental principle at FDA is that Americans should have access to drugs that are safe and effective for their FDA-indicated use. And guiding those decisions is the best available evidence with core scientific principle, just like any other area regulated by the FDA.”
“I am aware, as are you, that FDA has filed a court document indicating that its review of the REMS data on Mifepristone is soon going to be available,” he continued. “As you know in this position I am in now, I am not involved in those
The remainder of this article is available in its entirety at LifeSite News
The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors
